| Title |
Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry
|
|---|---|
| Published in |
Gastric Cancer, April 2017
|
| DOI | 10.1007/s10120-017-0718-5 |
| Pubmed ID | |
| Authors |
A. Carmona-Bayonas, P. Jiménez-Fonseca, A. Custodio, M. Sánchez Cánovas, R. Hernández, C. Pericay, I. Echavarria, A. Lacalle, L. Visa, A. Rodríguez Palomo, M. Mangas, J. M. Cano, E. Buxo, F. Álvarez-Manceñido, T. García, J. E. Lorenzo, M. Ferrer-Cardona, A. Viudez, A. Azkarate, A. Ramchandani, D. Arias, F. Longo, C. López, R. Sánchez Bayona, M. L. Limón, A. Díaz-Serrano, A. Fernández Montes, P. Sala, P. Cerdá, F. Rivera, J. Gallego, AGAMENON study group |
| Abstract |
Although anthracycline-based triplets are one of the most widely used schedules to treat advanced gastric cancer (AGC), the benefit of including epirubicin in these therapeutic combinations remains unknown. This study aims to evaluate both the efficacy and tolerance of triplets with epirubicin vs. doublets with platinum-fluoropyrimidine in a national AGC registry. Patients with AGC treated with polychemotherapy without trastuzumab at 28 hospitals in Spain between 2008 and 2016 were included. The effect of anthracycline-based triplets against doublets was evaluated by propensity score matching (PSM) and Cox proportional hazards (PH) regression. A total of 1002 patients were included (doublets, n = 653; anthracycline-based triplets, n = 349). The multivariable Cox PH regression failed to detect significantly increased OS in favor of triplets with anthracyclines: HR 0.90 (95% CI, 0.78-1.05), p = 0.20035. After PSM, the sample contained 325 pairs with similar baseline characteristics. This method was also unable to reveal an increase in OS: 10.5 (95% CI, 9.7-12.3) vs. 9.9 (95% CI, 9.2-11.4) months, HR 0.91 (CI 95%, 0.76-1.083), and (log-rank test, p = 0.226). Response rates (42.1 vs. 33.1%, p = 0.12) and PFS (HR 0.95, CI 95%, 0.80-1.13, log-rank test, p = 0.873) were not significantly higher with epirubicin-based regimens. The triplets were associated with greater grade 3-4 hematological toxicity, and increased hospitalization due to toxicity by 68%. The addition of epirubicin is viable, but 23.7% discontinued treatment because of adverse effects or patient decision. Anthracyclines added to platinum-fluoropyrimidine doublets did not improve the response rate or survival outcomes in patients with AGC but entailed greater toxicity. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 39 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 18% |
| Researcher | 6 | 15% |
| Other | 4 | 10% |
| Student > Master | 4 | 10% |
| Student > Postgraduate | 3 | 8% |
| Other | 5 | 13% |
| Unknown | 10 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
| Biochemistry, Genetics and Molecular Biology | 3 | 8% |
| Business, Management and Accounting | 1 | 3% |
| Decision Sciences | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 14 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 October 2018.
All research outputs
#14,801,390
of 22,963,381 outputs
Outputs from Gastric Cancer
#296
of 601 outputs
Outputs of similar age
#182,658
of 310,178 outputs
Outputs of similar age from Gastric Cancer
#4
of 10 outputs
Altmetric has tracked 22,963,381 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 601 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,178 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.